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Purpose. Keratolimbal allograft (KLAL) is a treatment for limbal stem cell deﬁciency. One disadvantage is systemic immunosup-
pression to avoid rejection. Our purpose was to examine the adverse eﬀects of systemic immunosuppression in KLAL. Methods.A
retrospective case review of 16 patients with KLAL who received systemic immunosuppression consisting of a corticosteroid, an
antimetabolite,and/oracalcineurininhibitorwasperformed.Patientsweremonitoredforsigns,symptoms,orlaboratoryevidence
of toxicity. Results. Eleven of 16 patients (68%) experienced an adverse eﬀect. The average age of those with adverse eﬀects was
43.5 years and without was 31.4 years. Ten of 11 patients (91%) had resolution during mean followup of 16.4 months. No serious
adverse eﬀects occurred. The most common included anemia, hyperglycemia, elevated creatinine, and elevated liver function tests.
Prednisoneandtacrolimuswereresponsibleforthemostadverseeﬀects.Patientswithcomorbiditiesweremorelikelytoexperience
an adverse eﬀect (82% versus 20%, P = 0.036). Conclusions. KLAL requires prolonged systemic immunosuppression. Our data
demonstrated that systemic immunosuppression did not result in serious adverse eﬀects in our population and is relatively safe
withmonitoringfortoxicity. Inaddition,wedemonstratedthatadverseeﬀectsaremorelikelyinolderpatientswithcomorbidities.
1.Introduction
Limbal stem cell deﬁciency can develop following destruc-
tion of the limbal epithelial stem cells (e.g., chemical injury),
or in conditions that impair the development or diﬀerentia-
tion of the limbal stem cells (e.g., aniridia). The prevalence
is unclear with only a fraction of patients with the above
conditions going on to develop deﬁciency. In limbal stem
cell deﬁciency, the cornea becomes covered by ingrowing
conjunctivalepitheliumleadingtorecurrentepithelialbreak-
down, neovascularization, and scarring with subsequent loss
of vision. Limbal stem cell transplantation is currently the
main surgical treatment for visually disabling, total limbal
stem cell deﬁciency. Keratolimbal allograft (KLAL) is the
surgical procedure of transplanting cadaveric limbal grafts
for patients with bilateral limbal stem cell deﬁciency, with a
reported success rate of around 73% at 5 years [1].
The postoperative management of patients after KLAL is
crucial to determining the long-term outcome of the pro-
cedure. Compared to conventional penetrating keratoplasty,
limbal allografts are at higher risk for rejection mainly be-
cause the limbal area is vascular, and thus more accessible
to the immune system, than the central cornea. Previous
studieshavedemonstratedtheimportanceoftopicalandoral
immunosuppression in maintaining graft survival. In one
series of aniridia patients treated with KLAL, the success rate
was 90% in patients receiving systemic immunosuppression
compared to 40% in patients treated with only topical im-
munosuppression [2].
TheKLALimmunosuppressionregimenissimilartothat
used in solid organ transplantation, where high rates of toxi-
city have been reported [3, 4]. The risks of immunosuppres-
sion must be balanced against the importance of the survival
of the graft for functional vision in these patients. Holland
and coworkers have recently demonstrated the relative safety
of systemic immunosuppression in patients receiving KLAL
and living-related conjunctival limbal allografts (lr-CLAL)
[5]. Our purpose was to examine the adverse eﬀects of
systemic immunosuppression in patients with keratolimbal
allograft.2 Journal of Ophthalmology
Table 1: Oral immunosuppression therapy regimen.
Class Starting dose Medication Number of
patients Avg. duration (months)
Corticosteroid 1mg/kg/day Prednisone 16 12.8 (Median:10, Range: 3–25)
Calcineurin inhibitor 3-4mg/kg/day Cyclosporine 4 13.7 (Range: 4–19)
2–4mg BID Tacrolimus 10 17.8 (Range: 5–25)
Antimetabolite 100–150mg/day Azathioprine 2 5.7 (Range: 1–16)
500–1000mg BID Mycophenolate mofetil 12 16.9 (Range: 5–39)
IL-2 inhibitor 2mg/day Sirolimus 1 22
2.MaterialandMethods
A retrospective case review was conducted on 16 patients
(19 eyes) with documented limbal stem cell deﬁciency that
underwent keratolimbal allograft at the University of Illinois
at Chicago Medical Center (UIMC) between January 2006
and June 2009. Institutional Review Board approval was
obtained. Written informed consent in accordance with the
Declaration of Helsinki was obtained from all patients. The
diagnosis of limbal stem cell deﬁciency was made based
on clinical ﬁndings including loss of the limbal palisades,
conjunctivalizationofthecornealsurface,superﬁcialneovas-
cularization, and nonhealing corneal epithelial defects. Prior
to surgery, patients were evaluated by their primary care
provider or an organ transplant specialist to determine their
eligibility for systemic immunosuppression. All operations
were performed by a single corneal surgeon (ARD) of the
Cornea Service of UIMC.
Postoperatively, all patients received prednisolone acetate
1.0% every 4–6 hours, gatiﬂoxacin 0.3% (Zymar, Allergan,
Irvine,CA)every6hours,andlubricationwithnonpreserved
artiﬁcial tears every 2 hours as needed. Once the corneal
epithelial defect had healed, gatiﬂoxacin 0.3% was discon-
tinued and cyclosporine 0.05% (Restasis, Allergan, Irvine,
CA) every 8 hours was started. Patients were examined for
graft function and signs of rejection every 1-2 weeks for
the ﬁrst month and every month thereafter. Acute rejection
episodes were managed with oral prednisone 1mg/kg/day,
prednisolone acetate 1.0% every 1-2 hours, and, in some
cases, a 0.2mL subconjunctival dexamethasone injection
(40mg/mL).
Systemic immunosuppression was initiated immediately
followingsurgerywithregimenslistedinTable 1.Allpatients
werestartedonaprednisonetaperstartingat1mg/kg/day.In
addition to prednisone, patients were started on tacrolimus
2–4mg twice daily to yield whole blood 12-hour troughs of
5–10ng/mL or cyclosporine (CsA) 3-4mg/kg/day daily to a
trough of 150–250ng/mL; mycophenolate mofetil (MMF)
500–1000mg twice daily or azathioprine 100–150mg daily.
Nine patients received tacrolimus plus MMF, and three
patients received CsA plus MMF. One patient received
tacrolimus plus sirolimus (Rapamune; Wyeth, Maidenhead,
United Kingdom) 1-2mg daily. Monotherapy with MMF,
azathioprine, or CsA was used in 3 other patients. Treatment
decisions were based on patient characteristics; for example,
the oldest patient (81 years) was treated with prednisone
and azathioprine alone, because it was felt that he did not
require as potent immunosuppression as younger patients.
The duration of treatment was determined based on ocu-
lar surface stability, deﬁned as absence of inﬂammation,
epithelial defects, and corneal neovascularization. Rejection
was deﬁned as presence of perilimbal injection, edema and
inﬁltration of the graft leading to epithelial defects, and
keratinization.
In coordination with an internist, complete blood count,
comprehensive metabolic proﬁle, renal and liver proﬁles,
fasting serum lipids, and fasting blood glucose were followed
every 1-2 weeks for one month and then every month there-
after.Alaboratoryvaluewasconsideredadverseifitoccurred
in two consecutive tests or if it prompted intervention.
Leukocytosis while on prednisone was not considered an
adverse eﬀect, since it did not alter management or have
a clear adverse consequence. Elevated intraocular pressure
and cataract were not recorded as adverse eﬀects and were
attributed to the concurrent use of topical steroids.
Prophylactic therapy was prescribed on a case-by-case
basis. Four patients with a history of herpes simplex virus
infection received valacyclovir (Valtrex) 500mg twice daily
for HSV prophylaxis. Three patients over 60 years received
trimethoprim-sulfamethoxazole for Pneumocystis carinii pro
-phylaxis. One patient that was known cytomegalovirus-
negative received valganciclovir (Valcyte) 900mg daily for
CMV prophylaxis.
3. Results
Nineteen eyes of 16 patients aged 10–81 years (mean 42.6
years, SD = 20.0) were treated with KLAL and systemic
immunosuppression and followed up for 4–39 months
(mean, 16.4 months). The etiologies of limbal stem cell
deﬁciency were aniridia (11 patients), chemical injury (2
patients), radiation therapy (1 patient), atopic keratocon-
junctivitis (1 patient), and idiopathic (1 patient). Five pa-
tients had bilateral KLAL and 6 patients had repeat KLAL,
3 of which had their ﬁrst procedure at an outside institution
prior to this study. At last followup, 15 of 19 (79%) allografts
were successful and 4 of 19 (21%) allografts had failed.
Ten of 16 patients (62%) had comorbidities. The most
common comorbidities at the time of transplantation were
hypertension and hyperlipidemia (4 patients each) followed
by hyperglycemia/diabetes mellitus (3 patients), asthma/
allergic rhinitis (2 patients), hypothyroidism (2 patients),Journal of Ophthalmology 3
Table 2: Adverse eﬀects of systemic immunosuppression.
Frequency
(Number
of patients)
Adverse eﬀect
(level) Adverse eﬀect status
2
Elevated
transaminases and
hyperbilirubinemia
(8.6, 3.8)
Resolved by switching
azathioprine to
mycophenolate; not
completely resolved possibly
from alcohol abuse
2 Elevated creatinine
(1.5, 1.6)
Resolved after
reducing/discontinuing
tacrolimus
2 Hyperglycemia
Treated with insulin; resolved
by increasing oral
hypoglycemic medication
2 Anemia (Hgb 11.9,
10.9)
Resolved with vitamin B12;
resolved with multivitamin
1 Hypomagnesemia
(1.6) Self-resolved
1 Worsening
hypertension
Resolved with increased
medication
1 Thrombocytopenia
(89)
Not yet resolved, possibly
from alcohol abuse
1A c n e Resolved after tapering oﬀ
prednisone and tacrolimus
1 Headache, tremors Resolved by decreasing
tacrolimus
1 Candida corneal
ulcer Resolved
1 HSV keratitis Resolved with oral acyclovir
1 (1.6) Self-resolved
ﬁbromyalgia (1 patient), and migraine (1 patient). One
patient had a history of elevated liver transaminases prior to
enrollment (history of alcohol abuse), however, was cleared
by their primary physician to be on immunosuppressive
therapy.
The most common immunosuppression regimen was
prednisone, MMF, and tacrolimus (9 patients). There was a
wide variation in duration of therapy, which was based on
the patient’s response to therapy, graft viability, and whether
the patient underwent a subsequent procedure. The general
goal was to taper oﬀ prednisone within 3–6 months and
to discontinue the other agents by 18–24 months. Four
of 16 patients (25%) had repeat or bilateral KLAL which
signiﬁcantly extended the average duration of therapy. For
example,thosereceivingasingleproceduretaperedto2.5mg
of prednisone by an average of 6.7 months versus 15 months
in those receiving multiple or repeat KLAL. Prednisone was
tapered to 10mg in 12 patients (75%) by 3 months. It was
tapered to 2.5mg in 8 patients (50%) by 6 months. Seven
patients were completely tapered oﬀ all immunosuppressive
medications without rejection.
Adverse eﬀects are summarized in Table 2. Five patients
(31.3%) experienced no adverse eﬀects. Abnormal lab values
were present in 7 patients (56%). Two diabetic patients had
hyperglycemia that required additional treatment (18.8%).
Two patients developed elevated creatinine (12.5%), one
of which was a diabetic. Two other patients had elevated
liver transaminases and hyperbilirubinemia (12.5%), one of
which also had anemia and thrombocytopenia. One other
patient developed anemia (6.3%) and one hypomagnesemia
(6.3%). One case of anemia resolved with a multivitamin,
and the other case resolved with vitamin B12. The abnormal
liverfunctiontestsresolvedafterswitchingfromazathioprine
to MMF however, remained mildly elevated in the patient
with possible alcohol abuse. One of the diabetic patients
who developed hyperglycemia was treated with insulin
and the other with additional oral hypoglycemic agents.
In both cases, the glucose control returned to baseline
upon prednisone taper. The elevated creatinine in one case
returned to normal upon reducing the dosage of tacrolimus,
however, remained mildly elevated in the diabetic patient
until tacrolimus was completely tapered oﬀ. The case of
hypomagnesemia resolved without intervention. Overall, the
only patient who had persistent laboratory abnormalities
was a patient with possible alcohol abuse who was lost to
followup.
Clinical adverse eﬀects were seen in 4 patients (25%):
One had hypertension (6.3%), 1 had headaches and tremors
(6.3%), 1 had acne (6.3%), 1 had HSV keratitis (6.3%), and
1h a dCandida albicans corneal ulcer (6.3%). The case of
headaches and tremors resolved with decreasing the dose
of tacrolimus. HSV keratitis was treated successfully with
oral acyclovir. The acne persisted after prednisone taper and
ﬁnally resolved upon discontinuing tacrolimus. The ulcer
resolved with therapeutic keratoplasty.
Theaverageageofthe11patientswithadverseeﬀectswas
43.5years(range10.8–81.6,SD = 20.8)andforthe5without
adverse eﬀects was 31.4 years (range 19.3–40.7, SD = 20.5).
Nine of 11 (82%) patients experiencing adverse eﬀects had
comorbidities, whereas only 1 of 5 (20%) patients without
adverse eﬀects had comorbidity. Comorbidities included
hypertension, diabetes, liver disease, hyperlipidemia, kidney
disease, and other chronic medical illnesses.
4. Discussion
KLAL is the main therapeutic option for bilateral, total
limbal stem cell deﬁciency. Due to the vascularity of the
limbal area, topical, and systemic multidrug immunosup-
pression is necessary to allow graft survival. Based on
the experience of solid organ transplantation, multidrug
regimens are preferred since they achieve a higher level
of immunosuppression with lower doses, and thus lower
toxicity, than individual medications used as monotherapy.
We present here a series of 16 patients who underwent
KLAL and systemic immunosuppression. Previously, the
adverse eﬀects of systemic immunosuppression with KLAL
have not been reported in such detail. Based on prior
studies by Holland and coworkers and our experience, our
preferred regimen is prednisone, mycophenolate mofetil,
and tacrolimus; nine of the patients in this series were on
this regimen. There was a wide variation in duration on
each medication, which was based on the patient’s response
to therapy, that is, signs of rejection or favorable response,4 Journal of Ophthalmology
as well as whether the patient underwent a subsequent
procedure, which required longer duration. The general goal
was to taper oﬀ prednisone within 3–6 months and to
discontinue the other agents by 12–18 months. In order
to achieve a more rapid taper of prednisone, we have
recently begun to use more potent topical steroids such as
diﬂuprednate (Durezol, Alcon, Irvine, CA). Our current goal
istodiscontinuetheoralsteroidsby3months.Antimicrobial
prophylaxis is used on a case-by-case basis.
Eleven (69%) patients experienced an adverse eﬀect to
systemic immunosuppression, and 10 of those patients
(91%) experienced resolution of the adverse eﬀect during
followup. There were no life-threatening complications.
T h em o s ts e r i o u sa d v e r s ee ﬀect was one case of Candida
albicans corneal ulcer. The corneal ulcer was attributed to
the patient’s preexisting ocular surface disease, while the
particular infectious agent was most likely due to topical
steroids.
Patients experiencing an adverse event were on average
older than the group without adverse events (43.5 versus
31.4 years, T-test P<0.05). In addition, those with
signiﬁcant comorbidities, including diabetes, hypertension,
kidney disease, liver disease, depressed immune systems,
and hyperlipidemia, were more likely to experience an
adverse event (82% versus 20%, P = 0.036). The most
adverse events were seen in patients with diabetes. For
example,onediabetichadproblemswithbloodsugar,kidney
function, and liver enzymes. In addition, one patient with
alcohol abuse had elevated liver enzymes, blood sugar,
and macrocytic anemia, making him a poor candidate for
systemic immunosuppression. We conclude from this data
that KLAL with systemic immunosuppression is relatively
contraindicated in older patients and those with signiﬁcant
comorbidities. However, in young and healthy patients, it
is rare to experience serious adverse eﬀects from systemic
immunosuppressioninKLAL,makingthemgreatcandidates
for the procedure.
Holland and coworkers (2007) have already demon-
strated in an age-matched study that ocular surface trans-
plant recipients experience signiﬁcantly fewer adverse eﬀects
to immunosuppression when compared to renal transplant
recipients [6]. Their group was the ﬁrst to suggest that
the patient population receiving ocular surface transplants
s u c ha sK L A Lm a yb em u c hm o r et o l e r a n to fs y s t e m i c
immunosuppression, likely owing to the relative abundance
of comorbidities in other solid organ transplant recipients
including hypertension, diabetes, kidney disease, and liver
disease. A recent study by Liang et al. demonstrated that only
2 of 10 (20%) patients on combined mycophenolate mofetil
and tacrolimus experienced adverse eﬀects, which included
hypertension, hyperbilirubinemia, and GI symptoms [7].
Similar data has been demonstrated in the use of
immunosuppression for other ocular diseases. In one study
of over 2000 patients receiving immunosuppression for ocu-
lar inﬂammation found no increased mortality from cancer
in patients receiving antimetabolites (methotrexate, aza-
thioprine, and mycophenolate mofetil) or T-cell inhibitors
(CsA) for eye disease [8]. A study of 373 patients taking
CsA for ocular inﬂammation reported only 13% stopping
treatment for an adverse eﬀe c t ,w h i c hw e r em o s tc o m m o n l y
renal toxicity or hypertension. They also demonstrated a
severalfold increase in discontinuation in patients greater
than 55 years of age compared to younger patients [9]. In
a similar study, of 236 patients treated with MMF, only 12%
withdrew due to adverse eﬀects, with most of these resolving
after discontinuation [10].
In corneal transplant surgery, a study of 43 corneal
transplantpatientsreceivingtacrolimusfoundadverseeﬀects
in 24 of 43 (56%) including 4 with lab abnormalities and
17 with symptoms such as headache, malaise, GI symptoms,
paresthesia, or insomnia. One patient developed pancreatitis
[11]. Another study showed that 6 of 29 (21%) receiving
MMF and 11 of 27 (41%) receiving CsA experienced an
adverse eﬀect at doses similar to our regimen, most com-
monly hepatotoxicity (3 and 2, resp.) and hypertension (3
and0,resp.).WhileonCsA,onepatientdevelopedHodgkin’s
lymphoma and one patient had a recurrence of acoustic
neuroma [12]. Another corneal transplant study showed that
22of49(44.9%)receivingCsAexperiencedanadverseeﬀect,
including 10 with lab abnormalities, 4 with hypertension,
and 6 with symptoms such as nausea/vomiting, backache,
or tremors [13]. Looking speciﬁcally at limbal-keratoplasty
utilizing CsA and/or MMF, one study of 48 patients showed
elevated creatinine in 9, liver enzymes in 6, and blood
pressure in 5 patients [14]. Another study showed that 1
of 3 patients receiving CsA had elevated creatinine [15].
In a study mentioned previously, MMF, tacrolimus, and
prednisone were used in 23 cases of KLAL and lr-CLAL and
resulted in 0 serious adverse events, 4 temporary creatinine
elevations, and 2 transient transaminase elevations [5].
In contrast, Ekberg et al. (2007) showed signiﬁcant side
eﬀects in 43–53% of renal transplant patients receiving
cyclosporine and tacrolimus, including 1–2.7% with new-
onset diabetes, 25% with opportunistic infections, 9 patients
developed cancer, and 4 deaths were considered to be
caused by an adverse eﬀect of systemic immunosuppression
[3].
Our study demonstrates that with close monitoring
for signs, symptoms, and laboratory abnormalities caused
by drug toxicity, systemic immunosuppression in KLAL is
generally safe. Patient selection and expectation is critical; it
is expected that patients with signiﬁcant comorbidities such
as diabetes and older age will be more likely to experience
adverse eﬀects, and, therefore, caution must be exercised in
such patients.
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